40 results about "D lactate" patented technology

Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.

The invention relates to a composition with disintoxicating and liver-protecting effects, which comprises the following raw materials in percentage by mass: 0.15 to 5 percent of crucumin, 0.04 to 1.0 percent of zinc lactate, 10 to 50 percent of glutamine, 10 to 50 percent of alanine and 10 to 50 percent of xylooligosaccharide. It is proved that, by an animal experiment and a human tasting experiment, the composition increases the alcohol dehydrogenase and acetaldehyde dehydrogenase content of a body and rapidly decomposes alcohol, so that the composition has the effects of promoting alcohol metabolism in a liver and reducing the alcohol concentration and active oxygen concentration in a blood; and the composition increases an endurance capacity of a human body to the alcohol, reduces the discomforts such as headache, nausea, vomiting and the like due to the alcohol, and reduces the damages of the alcohol to the liver. The composition can be prepared into food and health-care food with the disintoxicating and liver-protecting effects, can be used as a disintoxicating product for preventing and improving excessive drinking, and can be used as an adjuvant therapy product for an alcoholic liver, a fatty liver due to the alcohol or non-alcohol and protecting the liver; and the composition has the advantages of safety, non-toxicity and a reliable curative effect.

The invention discloses an in-situ implantation drug delivery system of microsphere-hydrogel matrix of detoxification drug naltrexone, belonging to the field of medicinal preparation. The drug naltrexone is embedded in microspheres of biodegradable materials polylactic acid/glycolic acid polymer; the microspheres disperse in reverse temperature sensitive hydrosol of methylcellulose; the hydrosol is solidified into a hydrogel matrix at body temperature during hypodermic injection to form a composite system of microsphere-hydrogel matrix and to control the release of naltrexone. The invention integrates the advantages of medicine carrying controlled release particles and temperature sensitive gel matrix in-situ implantation system, realizes injected implantation, realizes release at a constant speed for 60 days after implantation, and can adjust drug release speed by adjusting the content of naltrexone microspheres in hydrogel, thus having great significance in improving clinical application effect of naltrexone and in solving the problem of relapse in the detoxification process.

The invention provides a Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases and resisting fatigue, which comprises the following components in part by weight: 30 to 90 parts of glossy ganoderma extract, 40 to 120 percent of notoginseng root extract, 40 to 120 parts of root of red-rooted salvia extract and 40 to 120 parts of ginkgo leaf extract. The Chinese medicinal composition has the effects of regulating blood fat, improving hemorheology and resisting atherosclerosis, anoxia and fatigue, can reduce the level of lactic acid and serum urea and can relieve the discomfort feeling of limb weakness, oscitancy, muscular soreness, anorexia and the like which are caused by sports effectively. The invention also provides a Chinese medicinal preparation containing the Chinese medicinal composition and a preparation method thereof.

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

The invention provides a method for preparing compound of xylitol and lactic acid; the solution of the compound can directly wash vagina and cervix. The compound can cure or prevent colpitis and cervical erosion, can rapidly improve the congestion of vagina and cervix, can remove white or yellow purulent secretion, and can remove the inflammation of the vagina and cervix, thus recovering the health of the patient.

The invention discloses a method for preparing panaxoside and panaxynol through enzymatic zymotechnics. The method comprises the following steps: cleaning Changbai mountain ginseng, drying the ginseng at 50 to 60 DEG C, and crushing the ginseng to be 40 meshes; clustering raw material powder in hands, releasing namely dispersing the raw material power, adding mineral water to the raw material power, soaking the raw material power for 18 hours, and adjusting the PH value to be 4.5 to 6.5; putting mixed liquor into an enzymatic zymotechnics tank, adding enzymatic zymotechnics liquid to perform enzymatic zymotechnics, setting the enzymatic zymotechnics temperature to be 35 DEG C and the enzymatic zymotechnics time to be 72 hours, stirring and oxygenating once every 4 hours, and controlling the PH value to be 3.5 to 6.2; performing frame filtering, performing spray drying on supernate, ensuring that the drying temperature does not exceed 65 DEG C, and controlling the moisture to be lower than 7 percent to obtain powder; crushing the powder to be 120-mesh powder, then performing Co60 irradiation sterilization, and packing and warehousing finished products. The method is convenient in technology, easy to operate, low in energy consumption, clean and environment-friendly.

The present invention relates to a composition for the stabilization of glucose, lactate and homocysteine in blood after collection, to a use of the provided compositions and a method for the stabilization of glucose, lactate and homocysteine in blood after collection, as well as optionally the in vitro determination of glucose, lactate and homocysteine in blood, and a blood collection device provided for said use and method.

Amyotrophic lateral sclerosis (ALS) is a devastating disease that leads initially to death of motor nerves with some progression to death of sensory and autonomic nerves. Experimental work shows that more electrical energy is required to successfully stimulate motor vs. sensory nerve components of a nerve and longer vs. shorter components of a nerve. This discovery explains sparing of the nerves of ocular motion and nerves of rectal and urethral sphincters in patients suffering from ALS and supports the energy hypothesis of ALS. Neurons and peripheral nerves are dependent upon glial cells and oligodendrocytes respectively to support their high energy demands. These supporting cells shuttle lactate to neurons and nerves. Lactate is required to sustain contraction of skeletal muscle. Administration of racemic or L-lactate in an amount greater than the capacity of the liver to oxidize will increase the available lactate to nerves and neurons and improve the symptoms of ALS.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

The present invention refers to the new Escherichia coli strains denominated JU15, JU15A, LL26 and MS04 and their derivatives that produce metabolites, particularly D-lactate, L-lactate or ethanol, with high yield and selectivity from a wide variety of carbon sources, such as culture media with a high xylose content (as the main carbon source) and, in particular, media formulated with hydrolyzed vegetables, such as sugarcane bagasse, agave bagasse and fast-growing grasses, and a wide variety of agricultural and industrial wastes, such as whey or forestry wastes, celluloses, grasses, agave bagasse, paper wastes, shavings and sawdust, shrubs and generally any material derived from lignocellulose. These strains use the production of the metabolite of interest (especially D-lactate, L-lactate or ethanol) as the only way of regenerating the reducing power. The invention also refers to fermentation methods to produce these metabolites from media with a diversity of carbon sources, including glucose, lactose or xylose.

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

The invention relates to the field of medical reagents and discloses a flushing fluid containing sorbitol and mannitol and suitable for urologic surgeries. The flushing fluid is prepared from components as follows: 2.5wt%-2.9wt% of sorbitol, 0.5wt%-0.6wt% of mannitol and the balance of water for injection. The flushing fluid is mainly prepared from sorbitol and mannitol serving as main ingredients, adopts perfusion therapy through a proper urinary system instrument via the urethra and is applicable to flushing in the transurethral resection of the prostate and other urologic surgeries. The flushing fluid has the advantages as follows: 1) the flushing fluid is non-hemolytic; 2) the flushing fluid can also be used for diabetics; 3) the flushing fluid has a good diuretic function; 4) the flushing fluid can prevent blood coagulation in the surgeries, and a good intra-operative view can be kept; 5) the flushing fluid serving as a washing fluid used after the surgeries has a good blood coagulation prevention function; 6) the flushing fluid facilitates rapid excretion of sorbitol due to higher content of mannitol, and the potential risks of the sorbitol liver metabolite, namely, lactic acid are reduced.

The invention discloses a radioactive slow-release particle and a preparation method and the application thereof, pertaining to the field of radiation medicine. The particle mainly consists of <32> P-chromium phosphate and poly-L-lactic acid and can better solve the problem of targeted delivery of drugs in the treatment of tumors. The transplant of the particles in a tumor body or around a tumor can increase the local concentration of the drug, prolong the time of drug action and reduce systemic toxic and side effects.

The invention provides transgenic Escherichia coli cells comprising a mutation in cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene, wherein the mutation reduces (preferably, but not necessarily, by 100%) the cytochrome oxydase activity of a protein encoded by cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene. In a preferred embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, and cbdAB gene. In another embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, cbdAB gene, and ygiN gene. In another embodiment, the transgenic Escherichia coli cell, which comprises a deletion of cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene a) has substantially the same level of growth in oxic conditions as the level of growth in anoxic conditions of Escherichia coli that lacks said deletion of cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene, and b) is capable of converting glucose to D-lactate and/or amino acid and/or 2,3-butanediol (2,3-BDO) under one or both of oxic conditions and anoxic conditions.

The invention relates to the new application of the Chinese traditional medicine, in particular to the application of salvia extract, namely dihydroxyphenyl lactate in the treatment and prevention of thrombi. The test data indicate that the dihydroxyphenyl lactate can delay the time from the stimulation to the formation of thrombi and can prolong the half-volume time of the thrombi.

The invention discloses a trace element containing infant drinking water, characterized by that, each liter of RO pure water contains sodium fluoride 0.5-0.7mg, calcium powder 200-300mg, phosphatidy lcholine 150-200ug, ferric lactate 8-10mg, and glucose 100-250mg. The glutacid-containing nutritious drinking water according to the invention can be supplied to infants for direct drinking or as modulation food.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

A method of using a fertility enhancement food to improve human fertility. This fertility enhancement food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The fertility food, administered correctly, reduces cortisol levels. High cortisol interferes with conception and stable pregnancies. Dosage amounts are adjusted for client weight. Consumption frequency may be adjusted in response to cortisol measurements. Typically, consumption of the fertility food begins seven or more days before planned conception.